These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 29316337)
1. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337 [TBL] [Abstract][Full Text] [Related]
2. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658 [TBL] [Abstract][Full Text] [Related]
3. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity. Sheng W; Shang Y; Li L; Zhen Y Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279 [TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor. Sheng W; Shang Y; Miao Q; Li Y; Zhen Y Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154 [TBL] [Abstract][Full Text] [Related]
5. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin. Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325 [TBL] [Abstract][Full Text] [Related]
7. Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models. Gong J; Guo F; Cheng W; Fan H; Miao Q; Yang J Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):408-414. PubMed ID: 31913714 [TBL] [Abstract][Full Text] [Related]
9. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM. Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754 [TBL] [Abstract][Full Text] [Related]
10. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941 [TBL] [Abstract][Full Text] [Related]
11. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer. Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246 [TBL] [Abstract][Full Text] [Related]
12. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation. Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878 [TBL] [Abstract][Full Text] [Related]
13. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin. Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664 [TBL] [Abstract][Full Text] [Related]
14. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin. Jiang W; Shang B; Li L; Zhang S; Zhen Y Anticancer Drugs; 2016 Jan; 27(1):24-8. PubMed ID: 26457548 [TBL] [Abstract][Full Text] [Related]
15. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity. Zheng YB; Shang BY; Li Y; Zhen YS Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754 [TBL] [Abstract][Full Text] [Related]
16. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483 [TBL] [Abstract][Full Text] [Related]
17. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. He S; Zhao C; Tao H; Sheng W; Gao R; Liu X; Zhen Y Drug Deliv; 2022 Dec; 29(1):1243-1256. PubMed ID: 35416106 [TBL] [Abstract][Full Text] [Related]
18. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444 [TBL] [Abstract][Full Text] [Related]
19. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650 [TBL] [Abstract][Full Text] [Related]
20. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]